Avacta signs diagnostic licensing deal with Biokit


Cancer therapies and diagnostics group Avacta said it had entered into a license agreement with Biokit, a Werfen company, to incorporate its affimer reagents into a Biokit in-vitro diagnostic product.

'The license agreement follows an extensive evaluation by Biokit of certain Affimer reagents to detect a key analyte,' the company said.

Under the terms of the agreement, Biokit had the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners a diagnostic immunoassay for this analyte.

Avacta would receive royalties on future sales of any products brought to market following completion of product development and regulatory approvals.

At 9:55am: (LON:AVCT) Avacta Group PLC share price was 0p at 111.5p

Related content

Avacta signs distribution agreement with ABCAM for Covid-19 Affimer reagents

Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the company'sSARS-CoV-2 research Affimer reagents.

Under the worldwide, non-exclusive...

Tue, 06/04/2021 - 09:26

Avacta targets Covid-19 test kit launch by end of Q1; cancer drug trial to get underway by mid-2021

Avacta said it was targeting a launch of its Covid-19 test kit by around the end of the first quarter of this year, as the...

Wed, 24/02/2021 - 09:19

Avacta wins approval from UK health authorities for cancer drug trial

Affimer biotherapeutics and reagents group Avacta said it had received approval from UK health authorities to move ahead with with its trial of its lead...

Thu, 18/02/2021 - 09:55

Avacta says Covid-19 test shows 'excellent' performance in clinical studies

Affimer biotherapeutics and reagents developer Avacta said it had received the first data showing 'excellent performance' of its SARS-CoV-2 rapid antigen test from ongoing clinical...

Tue, 16/02/2021 - 09:22

Avacta teamsp up with Mologic to market Covid-19 tests

Biotherapeutics company Avacta said it had entered into a commercial partnership with Mologic to market the company's SARS-CoV-2 lateral flow rapid antigen test.


Mon, 08/02/2021 - 09:50